Investors in Medical Technology

Somudimec provides comprehensive financial support to companies throughout their lifecycle, including creation, development, or transfer phases. They cater to both ends of the balance sheet, offering a range of services such as leasing, factoring, balance sheet buyback, and credit insurance. Their holistic approach aims to meet diverse financial needs, supporting businesses with tailored solutions that facilitate growth and stability across different stages of their operations.

We invest money and experience in early stage medtech companies. The Blue Sparrows MedTech Fund invests money and experience in very early-stage medtech companies. The fund is unique in the fact that besides 2 experienced fund managers, a total of 7 young entrepreneurs in medical technology are part of the fund. The aim is to use their recent experience for the purpose of the investments made in the fund.

Thuja Capital invests in early stage medical product innovations. Thuja Capital is an early-stage venture capital firm located in Utrecht, The Netherlands. We invest in product focused companies that aim to have true impact for patients and doctors alike, as demonstrated in clinical studies to enable a health claim. Hence most of our ventures are active in the field of therapeutics, medical devices and digital health.

At Level2 Ventures, we’re on the lookout for innovative and compelling ideas, led by passionate and committed Founders who believe their solutions can change the world for the better. We understand the determination, hard work, trials, and errors it takes to achieve success. Recognizing the crucial role of capital in a company’s growth, we see it as just the first level of the support you need. Our offerings go beyond funding, encompassing managerial experience, talent recruitment, marketing, training, and proven operational strategies. We provide comprehensive support to help you navigate challenges and scale your business effectively.

Disruptive Technology Ventures is a privately held investment firm in disruptive technologies. We believe groundbreaking technologies can help resolve the big challenges the world is facing and can improve our lives. Our mission is to bring the most promising, unique and groundbreaking new technologies to the market in their optimal business model in order to deliver the impact these technologies deserve.

De Friesland recognizes that innovation is crucial for ensuring the accessibility and affordability of healthcare. That's why we actively invest in numerous organizations and projects dedicated to shaping a sustainable healthcare landscape. By supporting innovative initiatives, we aim to enhance the quality of care while addressing healthcare challenges effectively. Our commitment extends to fostering collaborations and partnerships that drive meaningful advancements in the sector.

Amadeus Capital Partners, we are a global technology investor headquartered in London, UK, with an office in Cambridge, UK. Since our founding in 1997, we have specialized in investing in high-growth technology companies across sectors such as Artificial Intelligence, Digital Health, Cybersecurity, Enterprise Software, and FinTech. Our track record demonstrates our commitment to backing ambitious entrepreneurs and supporting them in scaling their businesses internationally. We provide early-stage to growth-stage funding, partnering with founders from inception through to exit. Known for our deep sector expertise and global network, we take a hands-on approach to building successful and sustainable companies.

These two companies, FM INVEST & FM INVEST 2, primarily engage in activities in France and internationally, focusing on acquiring, subscribing to, holding, managing, and disposing of interests in companies or legal entities established domestically or abroad. They also specialize in wealth management consulting and financial engineering services.

SFINE is a passive holding company focused on investing in operational companies that meet specific criteria. These companies are typically unlisted and engaged in commercial, industrial, craft, liberal, or agricultural activities, excluding certain sectors like finance and real estate. SFINE targets companies in their seed, startup, or expansion phases, particularly those less than 7 years old or expanding into new markets or products. Based in the Essonne region of France, SFINE supports SMEs that contribute to economic growth while adhering to European Union standards for SMEs and de minimis aid.

INTELLAGRI CAPITAL specializes in financing and supporting innovative and transitional agriculture, leveraging a robust ecosystem for AgTech. They collaborate closely with the PURPAN Foundation and its network of engineers, PURPAN ALUMNI with a global reach, IRDI CAPITAL INVESTISSEMENT with extensive investment experience, and CREDIT AGRICOLE, a leading bank in France. This strategic alliance aims to foster growth and innovation within the agricultural sector by providing capital and expertise to AgTech startups and initiatives.

Seed for Good is a venture capital firm specializing in early-stage investments, targeting start-ups in pre-seed, seed, and series-A rounds. They focus on supporting innovative ventures that have the potential for significant growth and impact. Seed for Good provides not just financial backing but also strategic guidance and support to help entrepreneurs scale their businesses effectively. With a commitment to fostering sustainable and socially responsible businesses, they aim to create positive outcomes both commercially and socially through their investments.

The Joint Polish Investment Fund, ("JPIF") is a new Life Science Venture Capital Fund, which focuses on investments in Life Science companies with visible and near-term value inflection points and a prospective holding period of 3-5 years. JPIF consists of a team of people with broad experience in the life-science sector. Scientists and medical doctors with industrial experience work hand in glove with colleagues who have a thorough training in economics and business affairs. Everybody is driven by true interest in the life science field and new technologies, which will greatly contribute to people’s health disease management and quality of life. Entrepreneurs backed by JPIF have access to the knowledge and advice of each member of the JPIF team and to the associated global scientific and commercial network. Together JPIF and entrepreneurs are therefore in the position to accelerate preclinical, clinical or commercial development and a successful market entry into the most important healthcare markets: Europe, the U.S., and Asia.